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Abstract 1 
Background: Higher grip strength (GS) is associated with lower mortality risk. However, 2 
whether this association is independent of adiposity is uncertain. 3 
Objective: The purpose of this study was to examine the associations between GS, adiposity and 4 
mortality. 5 
Design: The UK Biobank study is an ongoing prospective cohort of >0.5 million UK adults aged 6 
40-69 years. Baseline data collection (2006-2010) included measurements of GS and adiposity 7 
indicators including body mass index (BMI). Age- and gender-specific GS quintiles were used. 8 
BMI was classified according to clinical cut-points. 9 
Results: Data from 403,199 participants were included in analyses. Over a median 7.0-year 10 
follow-up, 8,287 all-cause deaths occurred. The highest GS quintile had 32% (95% confidence 11 
interval [CI]: 26%, 38%) and 25% (95% CI: 16%, 33%) lower all-cause mortality risks in men 12 
and women, respectively, compared with the lowest GS quintile, after adjustment for 13 
confounders and BMI. Obesity class II (BMI≥35) was associated with greater all-cause mortality 14 
risks. Compared with the highest GS and normal weight category, the highest GS and Obesity 15 
class II category showed relatively higher all-cause mortality hazards (not statistically significant 16 
in men); however, the increased risk was relatively lower than the risk for the lowest GS and 17 
Obesity class II category. All-cause mortality risks were generally lower for obese but stronger 18 
individuals than for non-obese but weaker individuals. Similar patterns of associations were 19 
observed for cardiovascular mortality. 20 
Conclusions: Lower grip strength and excess adiposity are both independent predictors of higher 21 
mortality risk. The higher mortality risk associated with excess adiposity is attenuated, although 22 
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not completely attenuated, by greater GS. Interventions/polices should focus on improving 23 
muscular strength of the population regardless of their adiposity levels. 24 
Key words: grip strength, adiposity, muscle strength, obesity, mortality, UK Biobank25 
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Introduction 26 
Obesity is a global public health concern (1). Excess adiposity is known to be associated with 27 
greater risk of mortality as well as cardiovascular disease (CVD) such as heart failure, 28 
hypertension, and coronary heart disease (2). However, substantial evidence (3) suggests greater 29 
aerobic fitness can lower the risk of death and CVD associated with greater fatness. 30 
Muscular fitness, a complementary aspect of fitness, has also been found to be a strong predictor 31 
of mortality (4). As such, grip strength (GS), as a simple inexpensive measure of overall 32 
muscular strength (5-7), has been recognized as a useful prognostic indicator of mortality (8, 9) 33 
as well as adverse health outcomes, such as sarcopenia and frailty (10). A few studies (11-14) 34 
have attempted to further explore the “fit-fat” paradigm in relation to mortality and muscle 35 
strength, suggesting that mortality risk may be reduced in individuals with higher muscle 36 
strength irrespective of weight status. However, the evidence on the associations of muscle 37 
strength and fatness with mortality has been predicated primarily upon data with a relatively 38 
small sample size (<8000) of men (11, 12) or older adults (13). So, findings from these studies 39 
provide limited evidence on the relative risk of mortality for the combination of muscle strength 40 
and fatness for general adult populations. Furthermore, the majority of the studies have used 41 
body mass index (BMI) as a sole crude adiposity indicator (12-14). Abdominal adiposity defined 42 
by waist circumference (WC) predicts mortality independently of general adiposity (i.e. BMI, 43 
percent body fat [%BF]) (15). Hence, it is critical to discern the interactions of different 44 
adiposity indicators and muscle strength with mortality in general populations of men and 45 
women. Therefore, the purpose of the present analysis is to examine the relative risk of all-cause 46 
and CVD mortality for GS, various clinical adiposity measures (BMI, WC, %BF) and their 47 
interactions in middle-aged and older men and women.  48 
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 Subjects and Methods 49 
Study design and participants 50 
UK Biobank is an ongoing UK national cohort of over half a million adults aged 40-69 years at 51 
recruitment. Individuals were contacted who were registered with the National Health Service 52 
and living <25 miles away from one of 22 assessment centers across the UK. Of those, >500 000 53 
individuals performed baseline data collection (2006-2010) that included a wide variety of 54 
physical measurements and biological samples, as well as questionnaires on socio-demographic 55 
factors, family history/early-life exposures, general health/disabilities, environmental/lifestyle 56 
factors, and psychological/cognitive state. The UK Biobank methodology is described in detail 57 
elsewhere (16). All participants signed informed written consent prior to participation, and the 58 
protocol of the UK Biobank project was approved by the North West Multi-Centre Research 59 
Ethics Committee. 60 
Exposures 61 
Grip strength (GS) 62 
GS was assessed once in each hand using a Jamar J00105 hydraulic hand dynamometer, which 63 
can measure isometric grip force up to 90 kilograms (calibrated by staff at the start of each 64 
measurement day) showing good reliability and reproducibility (17). The handle of the device 65 
was adjustable to five grip positions between 1-3/8 and 3-3/8 inches. Participants were allowed 66 
to choose a grip position that they felt most comfortable with. Each participant was asked to 67 
grasp the handle of the device in their right hand while sitting upright on a chair with their 68 
forearm on the armrest. They were required to maintain a 90° angle of their elbow adjacent to 69 
their side so that their thumb would face upwards while squeezing the handle as strongly as 70 
possible for about 3 seconds. The same protocol was undertaken with the left hand. For the 71 
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current analysis, values from the two hands were averaged if available; otherwise, the value from 72 
a single hand was used in a small subsample (n=1,177). 73 
Adiposity measures 74 
BMI was calculated as measured weight (kg) divided by measured height (m) squared. WC was 75 
measured using a tape measure at the level of the umbilicus. Fat-free mass was assessed with the 76 
Tanita BC-418MA bio-impedance analyzer, from which %BF was calculated as 1 minus fat-free 77 
mass divided by body weight. BMI was categorized into normal weight (18.5-24.9 kg/m
2
), 78 
overweight (25.0-29.9 kg/m
2
), obesity class I (30.0-34.9 kg/m
2) and obesity class II (≥35.0 79 
kg/m
2
). The following sex-specific clinical cut-offs were applied to create three groups of WC 80 
and %BF: WC<94cm, 94-102cm or ≥102cm for men; WC<80cm, 80-88cm, or ≥88cm for 81 
women (1); %BF≤20%, 20-25% or >25% for men; and %BF≤30%, 30-33% or >33% for women 82 
(18). 83 
Outcomes 84 
Participants were followed up for mortality until February 15
th
 2016 through linkage with death 85 
records from the National Health Service Information Centre and the Scottish Morbidity Record. 86 
CVD mortality was defined as the International Classification of Diseases-10 codes F01 and I00-87 
I99. The median follow-up period was 7 years (interquartile range: 6.3 and 7.6 years). 88 
Covariates 89 
The following variables that could confound GS-mortality associations were included as 90 
covariates in the analyses: ethnicity (White, mixed, Asian/Asian British, Black/Black British, 91 
others), smoking status (never, previous, current), employment (unemployed, employed), 92 
Townsend Deprivation Index (a composite score of employment, car ownership, home 93 
ownership and household overcrowding, with higher values indicating a given area’s higher 94 
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degree of deprivation), statin use (yes/no), hormone replacement therapy (yes/no; women only), 95 
alcohol consumption (never, previous, currently <3times/week, currently ≥3times/week), 96 
processed/red meat consumption (days/week), resting pulse rate (beats/min), and moderate-to-97 
vigorous physical activity (MVPA) (minutes/day). MVPA time was estimated based on self-98 
reported walking, transportation activities, occupational activities/walking, strenuous/other 99 
exercise, and do-it-yourself activities by calibrating them to heart rate and accelerometry data 100 
(19) from 12 435 UK adults participating in the Fenland project (20).  101 
Statistical analyses 102 
Cox regression models (with age as the underlying time scale) were used to estimate associations 103 
of GS and adiposity with all-cause and CVD mortality. First, models were fit to estimate 104 
associations between GS and mortality, with adjustment for potential confounders (Model 1). 105 
Further adjustments for each of the three adiposity indicators (BMI, WC or %BF) were made in 106 
three separate models (Models 2a, 2b and 2c). In parallel with the models using GS as an 107 
exposure variable, models using each adiposity measure as an exposure variable were also fitted 108 
with adjustment for the same covariates (Model 1) and additional adjustments for GS (Model 2). 109 
Models using per-5kg increment in GS as an exposure were fitted by personal/lifestyle risk factor 110 
and disease status. GS-mortality associations were stratified by each adiposity variable. Gender- 111 
and age-specific quintiles of GS (Q1-Q5) and different adiposity categories were combined to 112 
examine joint associations with mortality. All analyses were performed for men and women 113 
separately. Subgroup analyses and tests of interaction between GS and age, weight status, waist 114 
circumference, %BF, MVPA, TV viewing, smoking, alcohol consumption, hypertension and 115 
diabetes were performed. Log-log plots provided support for the proportional hazards 116 
assumptions for all covariates. Sensitivity analyses were performed 1) using the maximum GS 117 
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from either hand, 2) GS normalized for body weight or fat-free mass to account for variation by 118 
body size, 3) excluding the first 2-year mortality follow-up, and 4) excluding individuals who 119 
had chronic obstructive pulmonary disease or were ‘current’/’previous’ smokers at baseline 120 
when examining adiposity as exposure (the latter two to minimize the risk of reverse causality). 121 
All analyses were performed in STATA/SE Version 14 (StataCorp LP, College Station, TX).  122 
Results 123 
Of an initial sample of 502,639 participants who undertook baseline data collection, individuals 124 
were excluded if they had a history of heart attack, stroke or cancer at baseline (n=55,401) to 125 
minimize the risk for reverse causality (8, 21), their censoring date was before the date of 126 
baseline data collection (n=3) or they had missing values on any of the variables (n=44,036), 127 
leaving 403,199 participants in the final analytic sample (Supplemental Figure 1).  128 
Table 1 shows participants’ characteristics across quintiles of GS. The specific cut-points to 129 
create the gender- and age-specific quintiles of GS are shown in Supplemental Table 1. A total of 130 
8,081 all-cause deaths occurred during 1,268,314 person-years of follow-up for men and 131 
1,533,538 person-years for women. Differences in BMI, WC, and %BF across quintiles of GS 132 
and the correlations between these variables (Supplemental Table 2) were minimal.   133 
Table 2 summarizes associations between GS and all-cause mortality. Compared with the lowest 134 
quintile of GS, the highest quintile of GS had considerably lower risks of all-cause mortality in 135 
both men and women (except for Q2) after adjusting for confounders (Model 1) plus additional 136 
adjustments for each adiposity measure (Model 2): p-values for trends <0.0001. Specifically, 137 
hazards of all-cause mortality were approximately 32% (95% confidence interval [CI]: 26%, 138 
38%) and 25% (95%CI: 16%, 33%) lower for men and women in Q5 of GS, respectively, 139 
compared with Q1 of GS after adjusting for confounders and BMI (Model 2a). The hazard ratios 140 
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(HR) for per-5kg increase in GS was 0.92 for both men (95%CI: 0.90, 0.93) and women (95%CI: 141 
0.89, 0.95) after adjusting for all confounders and BMI (Model 2a). Sensitivity analyses found 142 
similar associations with the maximal GS from either hand, and GS unnormalized or normalized 143 
for body weight or fat-free mass (Supplemental Figure 2). Another sensitivity analysis removing 144 
the first 2 years of follow-up yielded similar results (Supplemental Table 3). The pattern of 145 
associations of GS with CVD mortality was similar to the associations with all-cause mortality 146 
for men (Table 2). While the HRs were not statistically significant in women, p-values for linear 147 
trends were all less than 0.05. The associations of per-5kg increase in GS with all-cause and 148 
CVD mortality were significant (p-values<0.05) within almost all of the subgroups examined in 149 
both men and women (Figure 1), with some exceptions particularly for women.   150 
Associations of adiposity measures with all-cause and CVD mortality after adjusting for 151 
confounders (Model 1) and GS (Model 2) are shown in Supplemental Table 4. There were ‘J-152 
shaped’ associations between BMI and mortality risk (i.e. substantially lower all-cause mortality 153 
only in overweight men compared with normal weight men), which persisted even after 154 
excluding individuals who had chronic obstructive pulmonary disease and/or were 155 
‘current’/’previous’ smokers at baseline (Supplemental Table 5). The highest categories of BMI 156 
(i.e. obesity class II) and WC (i.e. abdominal obesity in men) were associated with increased 157 
hazards of all-cause and CVD mortality.  158 
Figure 2 shows joint associations of GS quintiles and adiposity categories with all-cause 159 
mortality. Compared with normal weight men with the highest level of GS, more obese men with 160 
lower GS had higher risks of all-cause mortality. For example, men with the highest level of 161 
BMI (i.e. Obesity class II) and lowest level of GS had a 89% higher risk of all-cause mortality 162 
(HR: 1.89; 95%CI: 1.50, 2.39) compared with the normal weight men with the highest GS. A 163 
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notable observation was the relatively higher mortality risks for normal weight men with lower 164 
GS in comparison with more obese men with higher GS. Similar trends of findings were 165 
observed with WC and %BF as adiposity indicators.  166 
Similarly, more obese women with lower GS had generally higher all-cause mortality risks 167 
compared with normal weight women with higher GS. The HR for women with the highest BMI 168 
level (i.e. Obesity class II) and lowest GS was 1.69 (95%CI: 1.32, 2.16) compared with normal 169 
weight women with the highest GS. The higher GS quintiles in the Obesity class II category 170 
were associated with significantly higher risks of all-cause mortality compared with the reference 171 
group. Joint analyses with WC and %BF as adiposity indicators found more obese women with 172 
higher GS to have lower all-cause mortality risks compared with non-obese women with lower 173 
GS. This pattern of associations was, in general, similar to the associations observed for CVD 174 
mortality (Figure 3).  175 
The lower GS quintiles had relatively higher all-cause (Supplemental Figure 3) and CVD 176 
mortality (Supplemental Figure 4) risks compared with the highest GS quintile within each 177 
adiposity stratum in both men and women. 178 
Discussion 179 
This study investigated the complex interplay of GS and various clinical adiposity measures with 180 
mortality from all causes and CVD in middle-aged and older men and women. Overall, greater 181 
GS was strongly associated with lower all-cause mortality risks, independently of adiposity 182 
measures. Moreover, every 5kg increment in GS was associated with about 8% lower hazard of 183 
mortality across nearly all subgroups defined by demographic and lifestyle risk factors or disease 184 
status. In contrast, adiposity measures had non-significant and/or inconsistent associations with 185 
mortality, although obesity class II and abdominal obesity were strong predictors of mortality, 186 
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independent of GS. The mortality risk was highest for men and women with the lowest level of 187 
GS and the highest level of adiposity in the combined analyses. More importantly, obese 188 
individuals with greater GS had lower or similar mortality risks compared with non-obese 189 
individuals with lower GS. The pattern of associations between GS and CVD mortality was 190 
comparable to the findings for all-cause mortality. Overall, our findings provide compelling 191 
rationales for developing interventions and policies to improve muscular strength and reduce 192 
excess adiposity to minimize mortality risk. 193 
The findings of this study are consistent with previous research by Leong at al. (9), which also 194 
demonstrated the high prognostic value of GS for various mortality and adverse health outcomes 195 
in 139,691 adults from 17 countries of different economic status. The HR of all-cause mortality 196 
for every 5kg reduction was 1.16 in Leong et al. study (9) but 1.08 (i.e. 1/0.92) in the present 197 
study. Some potential reasons for the difference are the use of gender- and age-specific quintiles 198 
of GS to take into account the inherent variation of GS by gender and age since GS is higher in 199 
men and younger individuals, and the exclusion of baseline medical conditions to minimize 200 
potential bias due to underlying subclinical conditions on GS and mortality in the present study. 201 
Furthermore, the use of a substantially larger sample allowed for comprehensive subgroup 202 
analyses by a number of lifestyle risk factors as well as disease status.  203 
The present study is generally consistent with the previous studies (11-14) in terms of the 204 
independent and joint associations of GS and adiposity with mortality outcomes. For instance, 205 
greater muscle strength predicted mortality independent of adiposity (11-14). In addition, the 206 
highest mortality risk was observed in individuals with the lowest muscle strength level and the 207 
highest adiposity level, implying the interactive impacts of muscle strength and adiposity on 208 
mortality (11, 12, 14). However, a novel observation of the present study is that strong obese 209 
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individuals had relatively lower mortality risks compared with weak non-obese individuals. This 210 
suggests that improving muscle strength may be a more important public health priority than 211 
reducing adiposity levels in decreasing mortality risks, although excessive adiposity itself is a 212 
strong risk factor for mortality (15). Another novel aspect of this study over the previous studies 213 
(11-14) is the use of a large cohort dataset, which enabled to create multiple sub-groups of GS 214 
and various clinical adiposity indicators in examining the joint associations with mortality in 215 
men and women separately.  216 
The present study found that men had more consistent associations between GS and mortality 217 
(independent of adiposity) than women, which is in line with previous research (13). There is 218 
also evidence on the weaker associations of GS with all-cause mortality for women (22). In this 219 
regard, convincing evidence suggests an age-related decline in muscle strength in women 220 
(particularly after menopause) can be prevented through estrogen-hormone replacement therapy 221 
(23). However, none of the previous studies (13, 22) included estrogen-hormone replacement 222 
therapy as a potential confounder in the models for women whereas the present study did. Our 223 
study clearly demonstrated lower mortality rates for both men and women with greater GS. 224 
Moreover, given that current public health guidelines (24) recommend that both men and women 225 
do muscle-strengthening activities at least twice a week, interventions and policies should be 226 
designed and implemented in a way to encourage both genders to engage in regular muscle-227 
strengthening activities, regardless of their adiposity levels.  228 
Compelling evidence suggests that resistance exercise can result in improvements in muscle 229 
strength (including GS) and neuromotor functions in healthy and clinical adult populations (25). 230 
It appears that muscle strength gained through resistance exercise can diminish rapidly after the 231 
termination of training, but its effects on neuromotor functions can be sustained for a relatively 232 
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long period of time even with a weekly session of moderate-to-vigorous intensity resistance 233 
exercise (25). We observed weak relationships between GS and adiposity measures, suggesting 234 
greater GS is determined based on better neuromotor functions rather than higher adiposity itself. 235 
Nonetheless, it is important to point out that the effects of resistance training are typically site-236 
specific (26), so training solely GS may not necessarily yield favorable effects on other parts of 237 
the body. Thus, efforts should be placed on improving whole-body muscle strength as well as 238 
neuromuscular functions.  239 
Effects of resistance training on reducing metabolic risk are also well-documented. Specifically, 240 
glucose metabolisms and insulin sensitivity can be enhanced in response to resistance exercise 241 
(27). In the present study, the prevalence of diabetes was lower in both men and women across 242 
incremental GS quintiles. It may be that participation in resistance training was higher in those 243 
with greater GS since people use their hands in most upper-body resistance training. This 244 
suggests individuals with greater muscle strength may sustain metabolically healthier lives. 245 
Furthermore, a meta-analysis of randomized-controlled trials concluded that resistance training 246 
programs reduced levels of lipids and lipoproteins circulating in the blood stream (28). However, 247 
high-intensity resistance training may increase arterial stiffness (29), which may then increase 248 
the risk of mortality and CVD (30). More evidence is needed to determine the specific dose-249 
response relationship between resistance training and health outcomes.   250 
This study is not without limitations. First, the use of data from an observational prospective 251 
study cannot fully determine causal relationships between GS and mortality. However, we 252 
excluded individuals with critical medical conditions at baseline in the primary analysis, and 253 
further excluded individuals who died in the first 2 years of follow-up and individuals who had 254 
respiratory disease or were current or previous smokers at baseline in the sensitivity analysis, in 255 
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order to minimize the risk for reverse causality. Second, due to the lack of sampling strategies for 256 
recruiting samples in UK Biobank, results of this study may only be generalizable to those of 257 
similar characteristics to the sample analyzed here. Another limitation is the measurement 258 
method for aerobic fitness, a strong mortality predictor (31). Ideally, this is measured as oxygen 259 
consumption during maximal exercise tests. We adjusted for resting pulse rate instead, which is 260 
strongly associated with maximal oxygen consumption (32). The relatively low number of death 261 
cases in the analysis for CVD mortality is another limitation. Finally, the use of self-reported 262 
data for some of the covariates may have increased the risk of residual confounding.  263 
Conclusions 264 
Men and women with greater GS had lower risks of all-cause and CVD mortality, independent of 265 
adiposity. While excess adiposity per se presents substantial risk of mortality, the risk associated 266 
with excess adiposity was reduced, although not completely eliminated, through greater GS. 267 
Public health efforts should aim to improve muscle strength of the population in all adiposity 268 
levels.  269 
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Table 1. Participants’ characteristics 
 Men (n=183,006) Women (n=220,193) 
 All Quintiles of grip strength All Quintiles of grip strength 
Variables   Q1 Q2  Q3 Q4 Q5   Q1  Q2  Q3  Q4  Q5  
Grip strength, kg 39.7 (8.8) 27.7 (4.9) 35.3 (26) 39.3 (2.7) 43.6 (2.9) 51.2 (4.9) 23.5 (6.2) 14.7 (3.6) 20.2 (2.1) 22.9 (2.1) 26.2 (2.1) 31.2 (3.5) 
Age, years 56.2 (8.2) 56.4 (8.4) 55.8 (8.3) 56.5 (8.1) 56.5 (8.2) 55.6 (8.1) 56.0 (8.0) 56.7 (8.0) 55.8 (8.2) 56.5 (8.0) 55.7 (7.7) 55.4 (8.1) 
Ethnicity, %             
     White 94.4% 89.6% 93.7% 95.5% 96.3% 96.6% 94.4% 90.9% 94.0% 95.1% 95.9% 95.6% 
     Mixed 0.5% 0.5% 0.6% 0.5% 0.5% 0.5% 0.7% 0.7% 0.7% 0.6% 0.7% 0.8% 
     Asian/Asian British 2.6% 6.3% 3.2% 2.0% 1.2% 0.7% 2.1% 5.0% 2.5% 1.7% 1.2% 0.6% 
     Black/Black British 1.6% 2.0% 1.5% 1.4% 1.4% 1.7% 1.8% 1.8% 1.6% 1.7% 1.5% 2.4% 
     Others 0.9% 1.6% 1.0% 0.7% 0.7% 0.5% 1.0% 1.6% 1.1% 0.9% 0.8% 0.6% 
Smoking status, %             
     Never 50.4% 51.4% 50.9% 50.7% 49.6% 49.7% 60.3% 61.6% 61.4% 60.5% 59.6% 58.8% 
     Previous 37.3% 35.0% 36.5% 37.1% 38.7% 38.9% 31.0% 29.2% 29.9% 31.3% 31.7% 32.5% 
     Current 12.3% 13.6% 12.6% 12.1% 11.7% 11.4% 8.7% 9.2% 8.7% 8.2% 8.7% 8.7% 
Employment, %             
     Unemployed 35.9% 42.2% 35.3% 36.0% 35.6% 30.9% 43.0% 50.2% 42.4% 44.4% 39.3% 39.9% 
Townsend deprivation index -1.33 (3.1) -0.58 (3.4) -1.16 (3.1) -1.44 (3.0) -1.62 (2.9) -1.79 (2.8) -1.39 (3.0) -0.95 (3.2) -1.28 (3.0) -1.47 (3.0) -1.57 (2.9) -1.59 (2.9) 
Statin use, % 19.7% 23.6% 19.7% 19.8% 18.9% 16.8% 11.7% 15.4% 12.1% 11.5% 10.3% 10.0% 
Hormone replacement therapy 
(W), % 
(N/A) (N/A) (N/A) (N/A) (N/A) (N/A) 7.5% 7.4% 7.2% 7.2% 7.7% 7.9% 
Alcohol Consumption, %             
     Never 2.7% 4.7% 2.8% 2.4% 1.9% 1.6% 5.6% 9.1% 6.1% 5.1% 4.4% 4.1% 
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     Previous 3.3% 5.0% 3.4% 2.9% 2.7% 2.3% 3.4% 4.8% 3.7% 3.2% 2.9% 2.7% 
     Current (<3times/week) 41.8% 44.3% 42.7% 41.3% 40.3% 40.7% 53.7% 56.4% 55.1% 53.4% 52.9% 51.5% 
     Current (≥3times/week)  52.3% 45.9% 51.0% 53.5% 55.1% 55.3% 37.2% 29.8% 35.2% 38.2% 39.7% 41.7% 
Processed/red meat 
consumption, days/week 
1.04 (0.60) 1.05 (0.64) 1.04 (0.61) 1.04 (0.59) 1.03 (0.58) 1.05 (0.58) 0.78 (0.50) 0.79 (0.53) 0.78 (0.50) 0.78 (0.50) 0.78 (0.49) 0.78 (0.49) 
Resting pulse rate, beats/min 68.3 (11.7) 69.5 (12.3) 68.4 (11.8) 68.0 (11.6) 67.9 (11.6) 67.9 (11.5) 70.1 (10.5) 70.8 (10.7) 70.1 (10.5) 69.9 (10.4) 69.8 (10.4) 69.9 (10.6) 
Self-reported MVPA time, 
min/day 
82.3 (22.9) 78.4 (20.7) 81.8 (22.2) 82.4 (24.0) 83.1 (23.0) 85.3 (23.6) 51.6 (19.5) 49.2 (16.1) 51.0 (18.8) 51.3 (18.8) 52.5 (19.5) 53.5 (22.9) 
BMI, kg/m2 27.7 (4.2) 27.7 (4.6) 27.6 (4.3) 27.6 (4.1) 27.7 (3.9) 28.2 (3.9) 27.0 (5.1) 27.6 (5.5) 26.9 (5.1) 26.8 (5.0) 26.8 (4.9) 27.0 (5.0) 
     Normal weight, % 25.0% 28.0% 27.8% 25.9% 24.3% 19.6% 39.2% 35.0% 39.9% 40.6% 41.0% 39.1% 
     Overweight, % 50.1% 46.2% 48.6% 50.6% 51.7% 52.9% 37.3% 37.0% 37.0% 37.3% 37.5% 37.7% 
     Obesity class I, % 19.4% 19.1% 18.0% 18.5% 19.3% 22.0% 15.8% 17.9% 15.7% 15.2% 14.8% 15.5% 
     Obesity class II, % 5.5% 6.7% 5.6% 5.0% 4.7% 5.5% 7.7% 10.1% 7.4% 6.9% 6.7% 7.6% 
 WC, cm 96.6 (11.1) 97.0 (12.0) 96.2 (11.4) 96.2 (11.0) 96.4 (10.7) 97.3 (10.5) 84.5 (12.4) 86.0 (13.1) 84.2 (12.3) 83.9 (12.1) 83.8 (12.1) 84.6 (12.2) 
     <94cm(M); <80cm(W)  45.3% 44.8% 47.5% 46.6% 46.0% 41.8% 42.5% 37.9% 43.2% 44.1% 44.4% 42.1% 
     94-102cm(M); 80-88cm(W) 25.4% 23.7% 24.5% 25.4% 25.7% 27.2% 21.9% 21.3% 21.8% 21.9% 22.1% 22.3% 
     ≥102cm(M); ≥88cm(W) 29.4% 31.5% 28.1% 28.0% 28.3% 30.9% 35.6% 40.8% 34.9% 34.0% 33.5% 35.6% 
%BF 25.1 (5.8) 25.8 (6.1) 25.2 (5.9) 25.0 (5.7) 24.8 (5.6) 24.7 (5.5) 36.4 (6.9) 37.5 (7.0) 36.5 (6.9) 36.4 (6.8) 36.1 (6.8) 36.0 (6.9) 
     ≤20%(M); ≤30%(W) 18.3% 16.5% 18.2% 18.8% 19.1% 18.9% 17.6% 14.4% 17.2% 17.5% 18.7% 19.5% 
     20-25%(M); 30-33%(W) 30.9% 27.5% 30.3% 31.0% 32.1% 33.1% 12.8% 11.2% 13.0% 12.8% 13.5% 13.4% 
     >25%(M); >33%(W) 50.8% 56.0% 51.5% 50.2% 48.8% 47.9% 69.6% 74.4% 69.8% 69.7% 67.8% 67.1% 
Fat free mass, kg 63.8 (7.8) 61.0 (8.0) 62.3 (7.5) 63.3 (7.3) 64.5 (7.1) 67.3 (7.4) 44.5 (5.0) 43.4 (5.2) 43.7 (4.8) 44.0 (4.7) 44.8 (4.7) 46.3 (4.9) 
Systolic blood pressure, mm Hg 140.9 (17.3) 139.2 (17.7) 139.8 (17.2) 141.1 (17.4) 142.0 (17.2) 142.3 (16.9) 135.0 (19.2) 134.3 (19.2) 133.8 (19.2) 135.2 (19.3) 135.1 (19.0) 136.1(19.1) 
24 
 
24 
 
Diastolic blood pressure, mm 
Hg 
84.3 (9.9) 83.2 (10.1) 83.8 (10.0) 84.3 (9.9) 84.8 (9.9) 85.4 (9.8) 80.7 (10.0) 80.2 (10.0) 80.1 (10.0) 80.5 (9.9) 80.8 (9.9) 81.5 (9.9) 
Hypertension, % 61.1% 60.3% 58.7% 60.9% 62.4% 62.8% 47.7% 49.3% 46.0% 47.9% 46.8% 48.6% 
Diabetes, % 6.1% 9.7% 6.5% 5.8% 4.9% 4.1% 3.4% 5.4% 3.6% 3.1% 2.8% 2.6% 
 Note: The quintiles of grip strength were gender- and age-specific. Body Mass Index (BMI) was used to categorize participants into 
normal weight (18.5kg/m
2≤BMI<25kg/m2), overweight (25kg/m2≤BMI<30kg/m2), obesity class I (30kg/m2≤BMI<35kg/m2) and 
obesity class II (BMI≥35kg/m2). Hypertension was defined as systolic/diastolic blood pressure ≥140/90mm Hg, reported physician 
diagnosis of hypertension, or reported medication use to regulate blood pressure. Participants were considered to have diabetes if they 
reported a physician diagnosis of diabetes, or taking glucose-lowering treatment. 
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Table 2. Independent associations of grip strength with all-cause and cardiovascular disease (CVD) mortality. 
      Hazard ratios (95% confidence interval) for mortality 
Mortality 
outcome 
Gender Comparisons Number 
of deaths 
Person-years 
of follow-up 
Mortality 
rate  
Model 1 Model 2a Model 2b Model 2c 
All-cause  Men  5,049 1,268,314 398.1     
  Quintiles of grip 
strength  
       
      Q1 (Reference) 1,389 241,358 575.5 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
      Q2  933 232,139 401.9 0.80 (0.73, 0.87) 0.81 (0.75, 0.88) 0.80 (0.73, 0.87) 0.80 (0.73, 0.87) 
      Q3  920 253,118 363.5 0.71 (0.65, 0.77) 0.72 (0.66, 0.78) 0.70 (0.65, 0.77) 0.71 (0.65, 0.77) 
      Q4  972 268,240 362.4 0.72 (0.66, 0.78) 0.73 (0.67, 0.79) 0.72 (0.66, 0.78) 0.72 (0.66, 0.78) 
      Q5  835 273,460 305.3 0.67 (0.62, 0.73) 0.68 (0.62, 0.74) 0.67 (0.61, 0.73) 0.67 (0.62, 0.74) 
      P for linear trend    <0.0001 <0.0001 <0.0001 <0.0001 
  Per 5kg increment in 
grip strength 
   0.91 (0.90, 0.93) 0.92 (0.90, 0.93) 0.91 (0.90, 0.93) 0.91 (0.90, 0.93) 
 Women   3,238 1,533,538 211.1     
  Quintiles of grip 
strength 
       
      Q1 (Reference) 746 270,638 275.6 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
      Q2  652 274,981 237.1 0.96 (0.86, 1.06) 0.97 (0.87, 1.08) 0.97 (0.87, 1.07) 0.96 (0.86, 1.06) 
      Q3  656 316,838 207.0 0.81 (0.73, 0.90) 0.82 (0.74, 0.91) 0.82 (0.74, 0.91) 0.81 (0.73, 0.90) 
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      Q4  592 323,506 182.0 0.79 (0.71, 0.88) 0.80 (0.72, 0.89) 0.80 (0.71, 0.89) 0.79 (0.71, 0.88) 
      Q5  592 347,576 170.3 0.74 (0.67, 0.83) 0.75 (0.67, 0.84) 0.74 (0.67, 0.83) 0.74 (0.67, 0.83) 
      P for linear trend    <0.0001 <0.0001 <0.0001 <.0001 
  Per 5kg increment in 
grip strength 
   0.91 (0.89, 0.94) 0.92 (0.89, 0.95) 0.91 (0.89, 0.94) 0.91 (0.89, 0.94) 
          
CVD  Men  1,256 1,268,314 99.0     
  Quintiles of grip 
strength  
       
      Q1 (Reference) 373 241,358 154.5 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
      Q2  246 232,139 106.0 0.81 (0.69, 0.96) 0.82 (0.70, 0.97) 0.81 (0.69, 0.95) 0.81 (0.69, 0.96) 
      Q3  222 253,118 87.7 0.66 (0.56, 0.78) 0.67 (0.56, 0.79) 0.67 (0.56, 0.79) 0.67 (0.57, 0.79) 
      Q4  235 268,240 87.6 0.68 (0.58, 0.81) 0.69 (0.58, 0.81) 0.68 (0.58, 0.81) 0.69 (0.58, 0.82) 
      Q5  180 273,460 65.8 0.58 (0.48, 0.69) 0.57 (0.47, 0.68) 0.57 (0.47, 0.68) 0.58 (0.48, 0.70) 
      P for linear trend    <0.0001 <0.0001 <0.0001 <0.0001 
  Per 5kg increment in 
grip strength 
   0.88 (0.84, 0.91) 0.88 (0.85, 0.91) 0.88 (0.85, 0.91) 0.88 (0.86, 0.92) 
 Women   485 1,533,538 31.6     
  Quintiles of grip 
strength 
       
      Q1 (Reference) 122 270,638 45.1 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
      Q2  98 274,981 35.6 0.93 (0.72, 1.22) 0.93 (0.71, 1.21) 0.95 (0.73, 1.24) 0.94 (0.72, 1.23) 
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      Q3  89 316,838 28.1 0.73 (0.56, 0.97) 0.72 (0.55, 0.95) 0.75 (0.57, 0.99) 0.74 (0.56, 0.97) 
      Q4  92 323,506 28.4 0.85 (0.65, 1.12) 0.83 (0.63, 1.10) 0.86 (0.65, 1.13) 0.85 (0.65, 1.12) 
      Q5  84 347,576 24.2 0.74 (0.56, 0.98) 0.73 (0.55, 0.97) 0.74 (0.56, 0.98) 0.74 (0.56, 0.98) 
      P for linear trend    0.028 0.021 0.021 0.027 
  Per 5kg increment in 
grip strength 
   0.93 (0.87, 0.99) 0.93 (0.86, 1.01) 0.94 (0.87, 1.01) 0.94 (0.87, 1.01) 
Note: All Cox regression models used age as the underlying time variable. The quintiles of grip strength were gender- and age-specific. Mortality rate is crude 
mortality rate per 100,000-person years 
Model 1: Adjusted for ethnicity (White, mixed, Asian/Asian British, Black/Black British, others), smoking status (never, previous, current), employment 
(unemployed, employed), Townsend Deprivation Index, statin use (yes/no), hormone replacement therapy (yes/no; women only), alcohol consumption (never, 
previous, currently <3times/week, currently ≥3times/week), processed/red meat consumption (days/week), resting pulse rate (beats/min), and moderate-to-
vigorous physical activity time (minutes/day). 
Model 2a: Adjusted for all confounders included in Model 1 plus body mass index. Cases with BMI<18.5 (n=369 for men; n=1,525 for women) were excluded. 
Model 2b: Adjusted for all confounders included in Model 1 plus waist circumference. 
Model 2c: Adjusted for all confounders included in Model 1 plus percent body fat.
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Figure Legends 
Figure 1. Associations of per-5kg increment of grip strength with all-cause and cardiovascular 
disease (CVD) mortality for men and women. Models (using age as the underlying time variable) 
were adjusted for ethnicity (White, mixed, Asian/Asian British, Black/Black British, others), 
smoking status (never, previous, current; except for models stratified by smoking status), 
employment (unemployed, employed), Townsend Deprivation Index, statin use (yes/no), 
hormone replacement therapy (yes/no; women only), alcohol consumption (never, previous, 
currently <3times/week, currently ≥3times/week; except for models stratified by alcohol 
consumption), processed/red meat consumption (days/week; except for models stratified by 
processed/red meat consumption), resting pulse rate (beats/min), moderate-to-vigorous physical 
activity (MVPA) time (minutes/day; except for models stratified by MVPA), and body mass 
index (BMI) (except for models stratified by BMI, waist circumference and percent body fat). 
Hypertension was defined as systolic/diastolic blood pressure ≥140/90mm Hg, reported 
physician diagnosis of hypertension, or reported medication use to regulate blood pressure. 
Participants were considered to have diabetes if they reported a physician diagnosis of diabetes, 
or taking glucose-lowering treatment. Mortality rate is crude mortality rate per 100,000-person 
years. Cases with BMI<18.5 (n=369 for men; n=1,525 for women) were excluded in the BMI-
stratified models. Abbreviations: HR – hazard ratio; CI – confidence interval; M – men; W– 
Women. 
Figure 2. Joint associations of grip strength and body mass index, waist circumference or percent 
body fat with all-cause mortality for men and women. All Cox regression models (using age as 
the underlying time variable) were adjusted for ethnicity (White, mixed, Asian/Asian British, 
Black/Black British, others), smoking status (never, previous, current), employment 
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(unemployed, employed), Townsend Deprivation Index, statin use (yes/no), hormone 
replacement therapy (yes/no; women only), alcohol consumption (never, previous, currently 
<3times/week, currently ≥3times/week), processed/red meat consumption (days/week), resting 
pulse rate (beats/min), and moderate-to-vigorous physical activity time (minutes/day). The 
quintiles of grip strength were gender- and age-specific. Mortality rate is crude mortality rate per 
100,000-person years. Cases with BMI<18.5 (n=369 for men; n=1,525 for women) were 
excluded in the models with BMI. Abbreviations: HR – hazard ratio; CI – confidence interval; M 
– men; W– Women. 
 
Figure 3. Joint associations of grip strength and body mass index, waist circumference or percent 
body fat with cardiovascular disease (CVD) mortality for men and women. All Cox regression 
models (using age as the underlying time variable) were adjusted for ethnicity (White, mixed, 
Asian/Asian British, Black/Black British, others), smoking status (never, previous, current), 
employment (unemployed, employed), Townsend Deprivation Index, statin use (yes/no), 
hormone replacement therapy (yes/no; women only), alcohol consumption (never, previous, 
currently <3times/week, currently ≥3times/week), processed/red meat consumption (days/week), 
resting pulse rate (beats/min), and moderate-to-vigorous physical activity time (minutes/day). 
The quintiles of grip strength were gender- and age-specific. Mortality rate is crude mortality 
rate per 100,000-person years. Cases with BMI<18.5 (n=369 for men; n=1,525 for women) were 
excluded in the models with BMI. Abbreviations: HR – hazard ratio; CI – confidence interval; M 
– men; W– Women. 
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